Metabolomics as a Key Integrator for "Omic" Advancement of Personalized Medicine and Future Therapies

Clinical and Translational Science

Volumn 5, Issue 3, 2012, Pages 285-288

  Eckhart, Andrea D ^a,b   Beebe, Kirk ^b   Milburn, Mike ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b METABOLON INC   (United States)

Author keywords

Biomarker; Genomics; Metabolome; Metabolomics; Personalized medicine; Proteomics

Indexed keywords

ADENOSINE A2B RECEPTOR; BETA GLOBIN; BIOLOGICAL MARKER; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE;

ARTICLE; AWARENESS; BIOLOGICAL ACTIVITY; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENOME ANALYSIS; GENOMICS; HUMAN; HYPERTENSION; METABOLOMICS; PERSONALIZED MEDICINE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEOMICS; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC DISEASES, INBORN; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; METABOLOMICS; MUTATION;

EID: 84862213123     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2011.00388.x     Document Type: Article

References (31)

1. Offit K.Personalized medicine: new genomics, old lessons. Hum Genet. 2011; 130: 3-14.
2. Collins F.Has the revolution arrived? Nature. 2010; 464: 674-675.
3. Robson M, Offit K.Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med. 2007; 357: 154-162.
4. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S.Kras, braf, pik3ca, and pten mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011; 12: 594-603.
5. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, et al. A common variant at the tert-clptm1l locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011; 43: 1210-1214.
6. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet. 2011; 21: 456-462.
7. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, et al. A genome-wide association study of bladder cancer identifies a new susceptibility locus within slc14a1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011; 20: 4282-4289.
8. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, Stevens VL, Chen C, Mondul AM, Travis RC, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011; 20: 3867-3875.
9. Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H, Kumar V, Chang ET, Rothman N, Cerhan JR, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large b-cell lymphoma. PLoS Genet. 2011; 7: e1001378
10. Thomas A, Lenglet S, Chaurand P, Deglon J, Mangin P, Mach F, Steffens S, Wolfender JL, Staub C. Mass spectrometry for the evaluation of cardiovascular diseases based on proteomics and lipidomics. Thromb Haemost. 2011; 106: 20-33.
11. Gerszten RE, Asnani A, Carr SA. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res. 2011; 109: 463-474.
12. Ala-Korpela M, Kangas AJ, Inouye M. Genome-wide association studies and systems biology: together at last. Trends Genet. 2011; 27: 493-498.
13. Baraldi E, Carraro S, Giordano G, Reniero F, Perilongo G, Zacchello F. Metabolomics: moving towards personalized medicine. Ital J Pediatr. 2009; 35:30.
14. Takei M, Ando Y, Saitoh W, Tanimoto T, Kiyosawa N, Manabe S, Sanbuissho A, Okazaki O, Iwabuchi H, Yamoto T, et al. Ethylene glycol monomethyl ether-induced toxicity is mediated through the inhibition of flavoprotein dehydrogenase enzyme family. Toxicol Sci. 2010; 118: 643-652.
15. Watson M, Roulston A, Belec L, Billot X, Marcellus R, Bedard D, Bernier C, Branchaud S, Chan H, Dairi K, et al. The small molecule gmx1778 is a potent inhibitor of nad+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol. 2009; 29: 5872-5888.
16. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wagele B, Altmaier E, Deloukas P, Erdmann J, Grundberg E, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011; 477: 54-60.
17. Zgoda-Pols JR, Chowdhury S, Wirth M, Milburn MV, Alexander DC, Alton KB. Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol. 2011; 255: 48-56.
18. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. Cancer-associated idh1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462: 739-744.
19. Abate-Shen C, Shen MM. Diagnostics: the prostate-cancer metabolome. Nature. 2009; 457: 799-800.
20. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457: 910-914.
21. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006; 440: 1073-1077.
22. Gladwin MT. Adenosine receptor crossroads in sickle cell disease. Nat Med. 2011; 17: 38-40.
23. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956; 178: 792-794.
24. Madigan C, Malik P.Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease. Expert Rev Mol Med. 2006; 8: 1-23.
25. Urbinati F, Madigan C, Malik P.Pathophysiology and therapy for haemoglobinopathies. Part II: thalassaemias. Expert Rev Mol Med. 2006; 8: 1-26.
26. Zhang Y, Dai Y, Wen J, Zhang W, Grenz A, Sun H, Tao L, Lu G, Alexander DC, Milburn MV, et al. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med. 2011; 17: 79-86.
27. Ledford H. Big science: the cancer genome challenge. Nature. 2010; 464: 972-974.
28. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268-274.
29. Pfeiffer T, Hoffmann R. Large-scale assessment of the effect of popularity on the reliability of research. PLoS One. 2009; 4: e5996.
30. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, Holm H, Sanna S, Kavousi M, Baumeister SE, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet. 2011; 43: 1131-1138.
31. Gieger C, Geistlinger L, Altmaier E, Hrabe de Angelis M, Kronenberg F, Meitinger T, Mewes HW, Wichmann HE, Weinberger KM, Adamski J, et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008; 4: e1000282.